These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 21452022)

  • 1. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
    Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
    Kaplan HG; Malmgren JA; Atwood M
    Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
    Curigliano G; Viale G; Bagnardi V; Fumagalli L; Locatelli M; Rotmensz N; Ghisini R; Colleoni M; Munzone E; Veronesi P; Zurrida S; Nolè F; Goldhirsch A
    J Clin Oncol; 2009 Dec; 27(34):5693-9. PubMed ID: 19884553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
    Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
    J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of metastatic spread in triple-negative breast cancer.
    Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
    Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
    Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D
    J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
    Park YH; Kim ST; Cho EY; Choi YL; Ok ON; Baek HJ; Lee JE; Nam SJ; Yang JH; Park W; Choi DH; Huh SJ; Ahn JS; Im YH
    Breast Cancer Res Treat; 2010 Feb; 119(3):653-61. PubMed ID: 19957028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.